StreetInsider.com News Articles

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 02 Jul 2026 16:05:00 -0400

CAMBRIDGE, Mass., July 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 3 newly-hired employees options to purchase an aggregate of 125,600 shares of Akebia’s common stock on June 30, 2026. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $1.14 per share, which is equal to the closing price of

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 02 Jul 2026 16:05:00 -0400

The options have an exercise price of $1.14 per share, which is equal to the closing price of

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 02 Jul 2026 16:05:00 -0400

The options have an exercise price of $1.14 per share, which is equal to the closing price of

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 02 Jul 2026 16:05:00 -0400

The options have an exercise price of $1.14 per share, which is equal to the closing price of

Form 4 Akebia Therapeutics, For: Jun 29 Filed by: Ostrowski Erik

Wed, 01 Jul 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260701/26721385.html

Form 4 Akebia Therapeutics, For: Jun 29 Filed by: Ostrowski Erik

Wed, 01 Jul 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260701/26721385.html

H.C. Wainwright Reiterates Buy Rating on Akebia Therapeutics (AKBA)

Wed, 01 Jul 2026 07:03:20 -0400

H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating and $6.00 price target on Akebia Therapeutics (NASDAQ: AKBA).

The analyst commented: "We highlight the announced interim analysis of the VOICE trial from AKBA and US Renal demonstrating improved safety outcomes for chronic kidney disease (CKD) patients treated with VAFSEO versus standard erythropoiesis-stimulating agent (ESA) therapy. We view this as an important win supporting adoption of differentiated VAFSEO treatment for CKD anemia patients on dialysis. Importantly, the improved safety outcomes are based on the characterized three times per week (TIW) dosing protocol, a regimen implemented for in-center VAFSEO dosing during the patient’s

Form 8-K Akebia Therapeutics, For: Jun 30

Tue, 30 Jun 2026 08:05:00 -0400

si-local-file:///var/storage/secattach/20260630/26710011.html

Form 8-K Akebia Therapeutics, For: Jun 30

Tue, 30 Jun 2026 08:05:00 -0400

si-local-file:///var/storage/secattach/20260630/26710011.html

Vafseo trial stopped early after interim data shows fewer hospitalizations

Tue, 30 Jun 2026 08:02:51 -0400

Akebia Therapeutics (Nasdaq: AKBA) and U.S. Renal Care (USRC) announced that the VOICE trial, a study comparing Vafseo (vadadustat) to erythropoiesis-stimulating agents (ESAs) in dialysis patients with anemia due to chronic kidney disease, was stopped early following a planned interim analysis.

The trial's primary investigator halted the study after an Independent Data Monitoring Committee and Trial Steering Committee recommended stopping based on prespecified criteria. The interim analysis, with a data cutoff of June 1, 2026, covered 2,116 enrolled patients.

Results showed a win odds of 1.16 (95% CI 1.06–1.28, p=0.0016) on the primary composite endpoint of all-cause mortality and all-cause hospitalization, meeting

Vafseo trial stopped early after interim data shows fewer hospitalizations

Tue, 30 Jun 2026 08:02:51 -0400

Results showed a win odds of 1.16 (95% CI 1.06–1.28, p=0.0016) on the primary composite endpoint of all-cause mortality and all-cause hospitalization, meeting

U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA

Tue, 30 Jun 2026 08:00:00 -0400

Vafseo® demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimen

Primary Investigator to stop trial on recommendation from Independent Data Monitoring Committee and Trial Steering Committee

Interim analysis on primary endpoint replicated safety outcomes reported in the recently published win odds analysis of the INNO2VATE clinical trial program

Akebia and USRC expect to submit data for presentation at an upcoming scientific meeting

CAMBRIDGE, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- Akebia

U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA

Tue, 30 Jun 2026 08:00:00 -0400

Vafseo® demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimen

Primary Investigator to stop trial on recommendation from Independent Data Monitoring Committee and Trial Steering Committee

Interim analysis on primary endpoint replicated safety outcomes reported in the recently published win odds analysis of the INNO2VATE clinical trial program

Akebia and USRC expect to submit data for presentation at an upcoming scientific meeting

CAMBRIDGE, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- Akebia

U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA

Tue, 30 Jun 2026 08:00:00 -0400

Vafseo® demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimen

Primary Investigator to stop trial on recommendation from Independent Data Monitoring Committee and Trial Steering Committee

Interim analysis on primary endpoint replicated safety outcomes reported in the recently published win odds analysis of the INNO2VATE clinical trial program

Akebia and USRC expect to submit data for presentation at an upcoming scientific meeting

CAMBRIDGE, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- Akebia

U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA

Tue, 30 Jun 2026 08:00:00 -0400

Vafseo® demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimen

Primary Investigator to stop trial on recommendation from Independent Data Monitoring Committee and Trial Steering Committee

Interim analysis on primary endpoint replicated safety outcomes reported in the recently published win odds analysis of the INNO2VATE clinical trial program

Akebia and USRC expect to submit data for presentation at an upcoming scientific meeting

CAMBRIDGE, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- Akebia

U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA

Tue, 30 Jun 2026 08:00:00 -0400

Vafseo® demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimen

Primary Investigator to stop trial on recommendation from Independent Data Monitoring Committee and Trial Steering Committee

Interim analysis on primary endpoint replicated safety outcomes reported in the recently published win odds analysis of the INNO2VATE clinical trial program

Akebia and USRC expect to submit data for presentation at an upcoming scientific meeting

CAMBRIDGE, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- Akebia

U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA

Tue, 30 Jun 2026 08:00:00 -0400

Vafseo® demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimen

Primary Investigator to stop trial on recommendation from Independent Data Monitoring Committee and Trial Steering Committee

Interim analysis on primary endpoint replicated safety outcomes reported in the recently published win odds analysis of the INNO2VATE clinical trial program

Akebia and USRC expect to submit data for presentation at an upcoming scientific meeting

CAMBRIDGE, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- Akebia

U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA

Tue, 30 Jun 2026 08:00:00 -0400

Vafseo® demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimen

Primary Investigator to stop trial on recommendation from Independent Data Monitoring Committee and Trial Steering Committee

Interim analysis on primary endpoint replicated safety outcomes reported in the recently published win odds analysis of the INNO2VATE clinical trial program

Akebia and USRC expect to submit data for presentation at an upcoming scientific meeting

CAMBRIDGE, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- Akebia

U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA

Tue, 30 Jun 2026 08:00:00 -0400

Vafseo® demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimen

Primary Investigator to stop trial on recommendation from Independent Data Monitoring Committee and Trial Steering Committee

Interim analysis on primary endpoint replicated safety outcomes reported in the recently published win odds analysis of the INNO2VATE clinical trial program

Akebia and USRC expect to submit data for presentation at an upcoming scientific meeting

CAMBRIDGE, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- Akebia

U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA

Tue, 30 Jun 2026 08:00:00 -0400

Vafseo® demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimen

Primary Investigator to stop trial on recommendation from Independent Data Monitoring Committee and Trial Steering Committee

Interim analysis on primary endpoint replicated safety outcomes reported in the recently published win odds analysis of the INNO2VATE clinical trial program

Akebia and USRC expect to submit data for presentation at an upcoming scientific meeting

CAMBRIDGE, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- Akebia

U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA

Tue, 30 Jun 2026 08:00:00 -0400

Vafseo® demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimen

Primary Investigator to stop trial on recommendation from Independent Data Monitoring Committee and Trial Steering Committee

Interim analysis on primary endpoint replicated safety outcomes reported in the recently published win odds analysis of the INNO2VATE clinical trial program

Akebia and USRC expect to submit data for presentation at an upcoming scientific meeting

CAMBRIDGE, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- Akebia

U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA

Tue, 30 Jun 2026 08:00:00 -0400

Vafseo® demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimen

Primary Investigator to stop trial on recommendation from Independent Data Monitoring Committee and Trial Steering Committee

Interim analysis on primary endpoint replicated safety outcomes reported in the recently published win odds analysis of the INNO2VATE clinical trial program

Akebia and USRC expect to submit data for presentation at an upcoming scientific meeting

CAMBRIDGE, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- Akebia

U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA

Tue, 30 Jun 2026 08:00:00 -0400

Vafseo® demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimen

Primary Investigator to stop trial on recommendation from Independent Data Monitoring Committee and Trial Steering Committee

Interim analysis on primary endpoint replicated safety outcomes reported in the recently published win odds analysis of the INNO2VATE clinical trial program

Akebia and USRC expect to submit data for presentation at an upcoming scientific meeting

CAMBRIDGE, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- Akebia

U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA

Tue, 30 Jun 2026 08:00:00 -0400

Vafseo® demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimen

Primary Investigator to stop trial on recommendation from Independent Data Monitoring Committee and Trial Steering Committee

Interim analysis on primary endpoint replicated safety outcomes reported in the recently published win odds analysis of the INNO2VATE clinical trial program

Akebia and USRC expect to submit data for presentation at an upcoming scientific meeting

CAMBRIDGE, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- Akebia

U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA

Tue, 30 Jun 2026 08:00:00 -0400

Vafseo® demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimen

Primary Investigator to stop trial on recommendation from Independent Data Monitoring Committee and Trial Steering Committee

Interim analysis on primary endpoint replicated safety outcomes reported in the recently published win odds analysis of the INNO2VATE clinical trial program

Akebia and USRC expect to submit data for presentation at an upcoming scientific meeting

CAMBRIDGE, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- Akebia